BIG FLATS, NY--(Marketwire - December 22, 2008) - X-GEN
Pharmaceuticals announced that it will begin marketing Acetazolamide
for Injection USP. The product is AP rated and equivalent to Diamox®(1)
by Duramed Pharmaceuticals. Acetazolamide for Injection USP is indicated
for adjunctive treatment of: edema due to congestive heart failure;
drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized
seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and
preoperatively in acute angle-closure glaucoma where delay of surgery is
desired in order to lower intraocular pressure.
Acetazolamide for Injection USP is supplied as a sterile, preservative-free
lyophilized powder. Each vial contains acetazolamide sodium equivalent to
500mg of acetazolamide. It is packaged in single vial cartons NDC#
39822-0190-1, and should be stored at 20° - 25° C (68° - 77° F) [See USP
Controlled Room Temperature].
X-GEN President and CEO Susan Badia points out that the introduction of
Acetazolamide for Injection USP is another demonstration of X-GEN's commitment to
reliable and affordable patient care. "Currently there is only one supplier
of Acetazolamide for Injection USP. Our launch of this product will ensure
consistent supply and steady, competitive price levels. We look forward to
serving the healthcare community as the preferred source for Acetazolamide
for Injection USP."
X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and
delivery of specialty pharmaceutical products which serve the healthcare
community as effective, generic treatment choices. X-GEN's expanding
product line offers a broad range of dosage forms including injectables,
anti-infective solutions, oral solids, and inhalants. For further
information about X-GEN Pharmaceuticals, call (866) 390-4411, or visit the
web-site at www.x-gen.us.
(1) Diamox® is a registered trademark of Duramed Pharmaceuticals.